Healthcare can be complicated.
Your cardiology news shouldn’t be.
Join thousands of cardiology leaders today.
Cardiovascular Disease July 14, 2025
Good News and Bad News – CV Deaths Are Changing July 14, 2025
Good news – overall heart disease deaths in the U.S. have declined significantly since 1970. The bad news? According to a recent AHA study, several complex heart conditions are becoming increasingly responsible for cardiovascular deaths. Searching for trends in CV mortality, Stanford researchers analyzed over 50 years of CDC data, revealing dramatic changes in cardiac […]
Cardiology July 10, 2025
Top 6 Cardiology Trends from 2025’s First Half July 10, 2025
The first half of 2025 is now over, and the world of cardiology keeps expanding. As we do every year, we’ve compiled a list of the top six stories of H1 – one for each month – to recap the big changes and innovations happening in cardiology. AI-ECG’s Hot Start and Fast Expansion 2025 kicked […]
Electrophysiology July 3, 2025
Kardium’s Quarter Billion Dollar PFA Raise July 3, 2025
Developing the best pulsed field ablation system in the world isn’t cheap, and Kardium’s new $250M financing round signals that the company now has enough funding to pursue that mission to its fullest. The fresh funding round follows impressive clinical data from Kardium’s PULSAR study presented at HRS 2025 that demonstrated the Globe System’s effectiveness […]
Structural Heart June 30, 2025
Foldax’s TRIA Mitral Valve Impresses at NYV June 30, 2025
The valve replacement space keeps adding contenders, and Foldax’s polymer-based TRIA Mitral Valve replacement showed compelling one-year results in its India Clinical Trial presented at New York Valves 2025, suggesting we could soon have an alternative to bovine tissue valves. Researchers tested the new surgical TRIA polymer valve on 67 patients (aged 19 to 67) […]
More Stories
Population Health June 26, 2025
Save the Planet to Save Our Hearts (From Microplastics) June 26, 2025
We’ve all cut down on plastic straws to save the sea turtles, but what about ourselves? A recent AHA study suggests there could be a link between ocean microplastic levels and cardiovascular disease in U.S. coastal counties, adding to a concerning trend of microplastics and CV risk. Researchers analyzed counties near waters with high and […]
Surgeries & Interventions June 23, 2025
Edwards’ Evoque Might Have More Adverse Events Than Previously Known June 23, 2025
Over a year after becoming the first FDA-approved transcatheter tricuspid valve replacement system, a new JACC study suggests Edwards Lifesciences’ Evoque TTVR system might have some risks that regulators hadn’t previously considered. Searching for more answers about Evoque’s real world risks, researchers pulled data from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database […]
Cardiac Imaging June 19, 2025
New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025
By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]
Cardiology Business June 19, 2025
Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025
Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]
Cardiac Imaging June 16, 2025
Beyond Hardware: Is AI the Answer to Making Cardiac Imaging More Accessible? June 16, 2025
Sponsored by Philips Healthcare Cardiac imaging has traditionally improved through hardware advances, enabling the speed needed for high-quality images. However, hardware is rapidly reaching its physical limitations in suppressing cardiac motion and represents a large financial investment. Today, software and AI are driving the next leap in cardiac image quality and motion control – offering […]
Cardiology Pharmaceuticals June 16, 2025
No Need to Discontinue Abelacimab Pre-Procedure June 16, 2025
A new analysis of AZALEA-TIMI 71 suggests Anthos Therapeutics’ abelacimab is capable of reducing major bleeding in patients with AFib undergoing invasive procedures. The sub-analysis examined a total of 920 procedures across 441 patients taking either abelacimab or rivaroxaban, with approximately 1-in-3 patients undergoing an invasive procedure over a median follow-up of 2.1 years. Researchers […]
Cardiology Pharmaceuticals June 12, 2025
Pharmacologic Preconditioning to Improve Outcomes in Patients Undergoing Cardiac Surgery June 12, 2025
The majority of patients undergoing cardiac surgery, especially those on cardiopulmonary bypass (CPB), experience post-operative complications such as new-onset atrial fibrillation (POAF) and acute kidney injury (AKI), largely driven by oxidative stress and inflammation. Several approaches have been explored to reduce complications following cardiac surgery, however, a clinically meaningful impact has yet to be realized. […]
Cardiology Pharmaceuticals June 12, 2025
FDA Approves a New BP Triple Polypill June 12, 2025
Bringing a more effective BP therapy to the U.S. market, the FDA approved George Medicines’ triple therapy polypill called Widaplik for patients with hypertension, making it the first of its kind to go to market in the U.S. Widaplik’s approval stems from two studies, including one comparing the polypill against placebo as an initial treatment […]
Surgeries & Interventions June 9, 2025
Contrast Use During PCI on the Decline June 9, 2025
New ACC registry data suggests interventional cardiologists are using less contrast for PCI procedures in the cath lab which helps reduce post-PCI acute kidney injury risks, but a deeper look tells us there’s still room for improvement. Searching for cath lab trends, researchers examined 3.12M unique PCI procedures performed by 3.6k physicians from 2018 to […]
Cardiology Pharmaceuticals June 5, 2025
Regeneron & Hansoh’s GLP-1 Deal June 5, 2025
Just a few weeks after the full results of SURMOUNT-5 crowned Eli Lilly’s GLP-1/GIP tirzepatide king of the GLP-1s, Regeneron announced it will pay Hansoh Pharma $80M upfront and up to $1.93B in milestone payments for its Phase 3-stage GLP-1/GIP drug, HS-20094. It’s the early testing edge that has Regeneron excited about Hansoh’s HS-20094, since […]
Cardiology Pharmaceuticals June 2, 2025
Deeper Answers from the ABYSS Trial June 2, 2025
Diving deeper into the ABYSS trial, a new sub-analysis suggests that patients with MI and preserved LVEF who stop taking their beta-blockers experience significant rises in heart rate and BP, potentially increasing their risk of adverse events. Now ABYSS’ new sub-analysis gives insights as to why beta-blockers help reduce adverse outcomes post-MI by examining the […]
Cardiology Business May 29, 2025
Boston Scientific Bows Out on TAVR May 29, 2025
Marking its departure from the TAVR market, Boston Scientific officially discontinued sales of its Acurate neo2 and Acurate Prime TAVR systems and will no longer seek approval from the FDA or other regulatory agencies. While there’s no one reason to blame for Boston’s decision, it’s likely the recent three way clinical comparison trial presented at […]
Surgeries & Interventions May 22, 2025
Navitor Versus Sapien 3 Ultra: Different in the Details May 22, 2025
One year data from the NAVULTRA study published in JACC suggests that Edwards’ Sapien 3 Ultra and Abbott’s Navitor intra-annular TAVR valves have similar short-term clinical outcomes, with a few key differences. The NAVULTRA study explored data from 4k TAVR patients who received either Navitor or Sapien 3 Ultra and found that all-cause mortality was […]
Cardiology Pharmaceuticals May 19, 2025
Wegovy Rapidly Lowers MACE Risk May 19, 2025
Getting us closer to understanding GLP-1s’ heart benefits, a post hoc analysis of the SELECT trial suggests that Novo Nordisk’s Wegovy (semaglutide) significantly reduces a patient’s MACE risk in just three months of treatment. Researchers analyzed the SELECT trial data by looking at CV events in the first three to six months following semaglutide treatment […]
Cardiology Pharmaceuticals May 15, 2025
Tirzepatide Beats Semaglutide in Weight Loss May 15, 2025
Has a king of the GLP-1s finally been crowned? Full results from the SURMOUNT-5 trial published in NEJM seem to suggest that Eli Lilly’s tirzepatide (Zepbound/Mounjarno) could be better than Novo Nordisk’s semaglutide (Wegovy/Ozempic). Weighing the weight loss benefits of each drug, SURMOUNT-5’s researchers randomized 751 obese patients without T2D to receive either tirzepatide (10mg/15mg) […]
Cardiology Testing May 12, 2025
Predicting ASCVD With Calprotectin May 12, 2025
Knowing which biomarkers to look for is critical to diagnosing and preventing ASCVD, and a new JAMA study suggests calprotectin could be the key to catching ASCVD early. So how does calprotectin predict ASCVD? To answer this, researchers measured calprotectin levels in plasma collected from 2.4k participants during Phase 2 of the Dallas Heart Study […]
Cardiology Pharmaceuticals May 8, 2025
Obicetrapib Puts on a Show May 8, 2025
Results from NewAmsterdam Pharma’s Phase 3 BROADWAY and TANDEM trials suggest that obicetrapib could be an effective LDL-C lowering treatment, both on its own or combined with another drug. TANDEM examined the effects of a fixed-dose obicetrapib/ezetimibe combination therapy and found… BROADWAY put on a one-man show for obicetrapib as a monotherapy to help confirm […]
Cardiology Pharmaceuticals May 8, 2025
Marea Makes Progress on MAR001 May 8, 2025
Marea Therapeutics presented positive data from the Phase 2a clinical trial of its fat-targeting monoclonal antibody, MAR001, that could help address lipid and metabolic drivers of ASCVD. To assess MAR001’s impact on remnant cholesterol and triglycerides, researchers randomized 55 patients with hypertriglyceridemia to one of three doses (150, 300, and 450mg) or placebo and found… […]
